other material
confidence high
sentiment positive
materiality 0.75
GRI Bio reports positive Phase 2a IPF data for GRI-0621; FVC +99 mL vs placebo
GRI Bio, Inc.
- Phase 2a (n=35) GRI-0621-IPF-02: placebo-adjusted FVC +99 mL at Week 12 overall, +139 mL on background SOC.
- FVC increase ≥30 mL in 39% of drug vs 20% placebo; 50% on SOC; decline ≥10% in 8% vs 20%.
- Nine mechanistic pillars supported by RNA-seq, flow cytometry, serum ECM; 18 transcripts FDR<0.05.
- No serious TEAEs (0% vs 8% placebo); less cough (0% vs 25%), dyspnea (4% vs 17%), diarrhea (17% vs 33%).
- Company plans 52-week study; data presented at ERS 2026.